Suchergebnisse - "Pagnini, Cristiano"

PubPharm (60)

1

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis : data from a real-world study

enthalten in: Expert opinion on pharmacotherapy | 2023

von Tursi, A. | Mocci, G. | Cingolani, L. | +49

2

Probiotics in COVID-19 pandemic : when evidence lacks, rationale can still ease the way

enthalten in: Minerva gastroenterology | 2023

von Pagnini, C. | DI Paolo, M. | D'Alba, L. | +6

3

Safety and Potential Role of Lactobacillus rhamnosus GG Administration as Monotherapy in Ulcerative Colitis Patients with Mild-Moderate Clinical Activity

enthalten in: Microorganisms | 2023

von Pagnini, C. | Di Paolo, M. | Urgesi, R. | +4

4

Application of validated bleeding risk scores for atrial fibrillation in obscure gastrointestinal bleeding patients increases videocapsule endoscopy's diagnostic yield : a retrospective monocentric study

enthalten in: International journal of colorectal disease | 2023

von Urgesi, R. | Pagnini, C. | De Angelis, F. | +7

5

Application of validated bleeding risk scores for atrial fibrillation in obscure gastrointestinal bleeding patients increases videocapsule endoscopy’s diagnostic yield: a retrospective monocentric study

enthalten in: International journal of colorectal disease | 2023

von Urgesi, R. | Pagnini, C. | De Angelis, F. | +7

6

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease : results from an Italian multicenter study

enthalten in: Expert opinion on biological therapy | 2023

von Mocci, G. | Tursi, A. | Maconi, G. | +61

7

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases : A Real-Life, Multicenter, Observational Study

enthalten in: Inflammatory bowel diseases | 2023

von Tursi, A. | Mocci, G. | Allegretta, L. | +47

ErratumIn: Inflamm Bowel Dis. 2022 Oct 3;28(10):e145. - PMID 35820045

8

Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease : A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2022

von Tursi, A. | Mocci, G. | Cuomo, A. | +89

9

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases : A Real-Life, Multicenter, Observational Study

enthalten in: Biomedicines | 2022

von Mocci, G. | Bodini, G. | Allegretta, L. | +13

10

Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases : a real-life multicenter, observational study in Italy

enthalten in: Expert opinion on biological therapy | 2022

von Tursi, A. | Mocci, G. | Allegretta, L. | +52

1
2
3
4
5
6
Nächster »
[6]